Effects of HBV and HCV Co-infection on Plasma Concentration, Efficacy and Hepatotoxicity of Efavirenz in HIV/AIDS Patients
PENG Wen-xiua, FU Qianga, DU Xiao-lia*, LI Tai-shengb*
a. Department of Pharmacy, b. Department of Infectious Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China
Abstract：OBJECTIVE To investigate the influence of HBV and HCV co-infection on the plasma concentrations, efficacy and hepatotoxicity of efavirenz in HIV/AIDS patients. METHODS The peripheral blood HIV RNA viral loads, CD4+ T-cells, liver function and plasma efavirenz concentrations of 494 cases of HIV monoinfected, HIV/HBV and HIV/HCV co-infected patients were determined by PCR, flow cytometry, automatic biochemical analysis and HPLC and statically compared. RESULTS The median (IQR) efavirenz concentrations at week 48 of HIV-monoinfected patients, HBV- and HCV-coinfected patients were 3.781 mg·L-1(3.012-4.980 mg·L-1), 3.057 mg·L-1(2.040-5.144 mg·L-1), 2.557 mg·L-1(2.212-4.334 mg·L-1), respectively (P<0.05), while the proportions of patients achieving partial and complete virus inhibition were 78.59%, 76.36%, and 100.00%, respectively. The mean±SD CD4 cell counts steadily increased over time from (290±118), (273±120), and (282±134)cells·mm-3 at baseline to (442±184), (457±221), and (391±151) cells·mm-3 at week 48, respectively(P<0.05). The indexes of liver functions were all basically within normal limits. CONCLUSION The immune reconstruction of most patients is smooth and they also have favorable prognosis. Co-infection with HBV or HCV will not cause accumulation of efavirenz or hepatic damage. Efavirenz is safe and effective for treatment-naive HIV/AIDS patients with HBV and HCV co-infection.
彭文绣, 付强, 杜小莉, 李太生. HBV/HCV共感染对依非韦伦在HIV/AIDS患者血药浓度、疗效及肝毒性的影响[J]. 中国药学杂志, 2019, 54(14): 1162-1168.
PENG Wen-xiu, FU Qiang, DU Xiao-li, LI Tai-sheng. Effects of HBV and HCV Co-infection on Plasma Concentration, Efficacy and Hepatotoxicity of Efavirenz in HIV/AIDS Patients. Chinese Pharmaceutical Journal, 2019, 54(14): 1162-1168.
CHEN X, HE J M, DING L S, et al. Prevalence of hepatitis B virus and hepatitis C virus in patients with human immunodeficiency virus infection in central China [J] . Arch Virol, 2013, 158(9):1889-1894.
[2]
ZHANG F, ZHU H, WU Y, et al. HIV, hepatitis B virus, and hepatitis C virus co-infection in patients in the China National Free Antiretroviral Treatment Program, 2010-12: a retrospective observational cohort study [J] .Lancet Infect Dis, 2014, 14(11):1065-1072.
[3]
XIE J, HAN Y, QIU Z, et al. Prevalence of hepatitis B and C viruses in HIV-positive patients in China: a cross-sectional study [J] . J Int Aids Soc, 2016, 19(1):20659.
[4]
ALTER M J. Epidemiology of viral hepatitis and HIV co-infection [J] . J Hepatol, 2006, 44(1 suppl):6-9.
[5]
MARZOLINI C, TELENTI A, DECOSTERD L A, et al. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients [J] . AIDS (London, England), 2001, 15(1):71-75.
[6]
MUTLIB A E, CHEN H, NEMETH G, et al. Liquid chromatography/mass spectrometry and high-field nuclear magnetic resonance characterization of novel mixed diconjugates of the non-nucleoside human immunodeficiency virus-1 reverse transcriptase inhibitor, efavirenz [J] . Drug Metab Dispos, 1999, 27(9):1045-1056.
[7]
SULKOWSKI M S, THOMAS D L, MEHTA S H, et al. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections [J] . Hepatology (Baltimore, Md), 2002, 35(1):182-189.
[8]
ENA J, AMADOR C, BENITO C, et al. Risk and determinants of developing severe liver toxicity during therapy with nevirapine-and efavirenz-containing regimens in HIV-infected patients [J] . Int J Std Aids, 2003, 14(11):776-781.
[9]
MARTIN-CARBONERO L, NUNEZ M, GONZALEZ-LAHOZ J, et al. Incidence of liver injury after beginning antiretroviral therapy with efavirenz or nevirapine [J] . Hiv Clin Trials, 2003, 4(2):115-120.
[10]
BOSSI P, COLIN D, BRICAIRE F, et al. Hypersensitivity syndrome associated with efavirenz therapy [J] . Clin Infect Dis, 2000, 30(1):227-228.
[11]
ANGEL-MORENO-MAROTO A, SUAREZ-CASTELLANO L, HERNANDEZ-CABRERA M, et al. Severe efavirenz-induced hypersensitivity syndrome (not-DRESS) with acute renal failure [J] . J Infect, 2006, 52(2):e39-40.
[12]
KAPPELHOFF B S, VAN LETH F, ROBINSON P A, et al. Are adverse events of nevirapine and efavirenz related to plasma concentrations? [J] . Antivir Ther, 2005, 10(4):489-498.
[13]
BICKEL M, STEPHAN C, ROTTMANN C, et al. Severe CNS side-effect and persistent high efavirenz plasma levels in a patient with HIV/HCV coinfection and liver cirrhosis [J] . Infect Dis, 2005, 37(6-7):520-522.
[14]
ROBERTSON S M, SCARSI K K, POSTELNICK M J, et al. Elevated plasma concentrations of protease inhibitors and nonnucleoside reverse transcriptase inhibitors in patients coinfected with human immunodeficiency virus and hepatitis B or C: case series and literature review [J] . Pharmacotherapy, 2005, 25(8):1068-1072.
[15]
BARREIRO P, RODRIGUEZ-NOVOA S, LABARGA P, et al. Influence of liver fibrosis stage on plasma levels of antiretroviral drugs in HIV-infected patients with chronic hepatitis C [J] . J Infect Dis, 2007, 195(7):973-979.
[16]
WANG L, LI T S, FU Q, et al. Simultaneous determination of indinavir and efavirenz in human plasma by HPLC [J] . Chin J Hosp Pharm(中国医院药学杂志), 2009, 29(6):454-457.
[17]
PEREIRA S A, CAIXAS U, BRANCO T, et al. Efavirenz concentrations in HIV-infected patients with and without viral hepatitis [J] . Br J Clin Pharmacol, 2008, 66(4):551-555.
[18]
MEYNARD J L, LACOMBE K, POIRIER J M, et al. Influence of liver fibrosis stage on plasma levels of efavirenz in HIV-infected patients with chronic hepatitis B or C [J] . J Antimicrob Chemother, 2009, 63(3):579-584.
[19]
DOMINGUEZ S, GHOSN J, PEYTAVIN G, et al. Impact of hepatitis C and liver fibrosis on antiretroviral plasma drug concentrations in HIV-HCV co-infected patients: the HEPADOSE study [J] . J Antimicrob Chemother, 2010, 65(11):2445-2449.
[20]
CALZA L, DANESE I, COLANGELI V, et al. Plasma concentrations of efavirenz, darunavir/ritonavir and raltegravir in HIV-HCV-coinfected patients without liver cirrhosis in comparison with HIV-monoinfected patients [J] . Infect Dis (London, England), 2015, 47(9):625-636.
[21]
PORCHE D J. Efavirenz [J] . J Assoc Nurses Aids Care, 2000, 11(3):95-98.
[22]
KHOO S H, GIBBONS S E, BACK D J. Therapeutic drug monitoring as a tool in treating HIV infection [J] . AIDS (London, England), 2001,15(suppl 5):171-181.
[23]
HOFFMAN J T, ROSSI S S, ESPINA-QUINTO R, et al. Determination of efavirenz in human dried blood spots by reversed-phase high-performance liquid chromatography with UV detection [J] . Ther Drug Monit, 2013, 35(2):203-208.
2019, Vol. 54 
